Highlight
The InEurHeart randomized controlled trial reveals that computed tomography (CT)-guided ventricular tachycardia (VT) ablation significantly reduces procedure time compared to conventional ablation approaches. It maintains comparable safety profiles and shows a substantial reduction in VT burden at one year, supporting CT integration as a promising tool in catheter ablation workflows for ischemic cardiomyopathy patients.
Study Background
Ventricular tachycardia (VT) is a life-threatening arrhythmia commonly occurring in patients with ischemic cardiomyopathy, notably after myocardial infarction. Catheter ablation remains a key therapeutic option for reducing recurrent VT episodes, especially in cases refractory to antiarrhythmic drugs. However, the procedure is technically challenging, often requiring experienced centers and prolonged operation times due to complex substrate mapping within scarred myocardium. The advent of pre-procedural imaging modalities, particularly computed tomography (CT), offers detailed anatomical substrate visualization that may facilitate targeted ablation, potentially reducing procedure complexity and duration. Prior single-center, non-randomized investigations have suggested clinical benefits of image integration, but randomized evidence has been limited.
Study Design
The InEurHeart trial is a multicenter, randomized controlled study conducted across 14 European centers involving 113 patients with prior myocardial infarction and clinically significant VT. Participants were randomized 1:1 to undergo either CT-guided catheter ablation or conventional ablation without pre-procedural imaging integration. The CT-guided approach utilized pre-acquired cardiac CT scans to integrate scar and anatomical segmentation for targeted ablation planning. The primary endpoint was procedural duration, hypothesizing that CT guidance would shorten total ablation time. Secondary endpoints encompassed efficacy indicators—such as VT incidence and burden post-procedure—as well as safety assessments including major adverse events and composite clinical outcomes.
Key Findings
Procedural Duration: The primary endpoint demonstrated that CT-guided ablation significantly decreased procedure time compared to conventional ablation. Intention-to-treat analysis showed a reduction from 149±51 minutes to 120±50 minutes (a 19% decrease; 95% confidence interval [CI] -32% to -7%; P=0.0027). The per-protocol analysis indicated an even more pronounced reduction to 107±38 minutes (28%; 95% CI -40% to -16%; P<0.0001). This confirms that integrating CT imaging facilitates more efficient ablation targeting and substrate navigation.
Safety Profile: Major adverse events occurred in 3.5% of patients in the conventional group vs 1.8% in the CT-guided group, with no statistically significant difference (risk difference -1.8%; 95% CI -7.9% to 4.3%). This indicates that CT guidance does not increase procedural risk and maintains favorable safety comparable to standard practice.
Efficacy Outcomes: VT-free survival at one year was 67.3% in the conventional group compared with 76.8% in the CT-guided group, a nonsignificant absolute increase of 9.5% (95% CI -10.4% to 29.4%; P=NS). Importantly, the VT burden (frequency and duration of arrhythmia episodes) decreased by 90% in the CT-guided arm, suggesting a substantial reduction in clinical arrhythmia impact despite similar survival rates free of VT recurrence.
Expert Commentary
This study provides compelling randomized evidence supporting the use of CT imaging to guide VT ablation in ischemic cardiomyopathy patients. The reduction in procedural duration is clinically relevant as it may reduce anesthesia time, procedural fatigue, and resource utilization, potentially enhancing patient throughput in high-volume centers. The safety equivalence reassures that image integration does not compromise procedural risk. Although VT recurrence-free survival was not statistically different, the marked VT burden reduction is clinically meaningful, translating into fewer ICD therapies and symptoms. Limitations include the focus on ischemic cardiomyopathy patients with prior infarction, so extrapolation to non-ischemic VT substrates warrants caution. Future studies could explore combined imaging modalities or real-time CT integration techniques to further refine ablation efficacy.
Conclusion
The InEurHeart trial establishes that computed tomography-guided ventricular tachycardia ablation significantly shortens procedure times with a favorable safety and efficacy profile compared to conventional ablation strategies in ischemic cardiomyopathy patients. This approach represents a valuable advancement in tailoring and streamlining VT ablation procedures, supporting broader implementation of pre-procedural imaging integration in electrophysiology practice. Further research will help delineate long-term outcomes and applicability to diverse VT populations.
Funding and Clinical Trials Registration
The study was conducted across multiple European centers with multicenter collaboration. Details regarding funding sources and clinical trials registration were not provided in the abstract but can be accessed through the original publication.
References
1. Sacher F, Reichlin T, Le Bloa M, et al. Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial. Eur Heart J. 2026 Jun 16;47(23):2951-2964. doi:10.1093/eurheartj/ehac312. PMID: 41667137.
2. Tung R, Shivkumar K. Ablation of ventricular tachycardia in structural heart disease: state of the art. Circulation. 2011;124(7):940-950.
3. Josephson ME, Anter E. Substrate mapping for ventricular tachycardia: assumptions and pitfalls. J Cardiovasc Electrophysiol. 2015; 26(11):1204-1212.
4. Komatsu Y, Nakasuka K, Fukuchi K, et al. Cardiac CT-based preprocedural planning for ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2020;31(3):528-535.
5. Marchlinski FE, Callans DJ. Mapping techniques for ventricular tachycardia ablation: From activation and entrainment to substrate modification. Heart Rhythm. 2015;12(8):1637-1643.